Company intelligence / Profile preview

Toralgen

Indianapolis, Indiana, United Statestoralgen.com ↗

Ownership: Private
Development stage: Other

Overview

Toralgen has demonstrated in preclinical studies that its poly-bile nanoparticle platform can protect and deliver biologic drugs orally, potentially replacing injections. The technology has shown promise in animal models for diabetes and autoimmune disease therapies. The company was accepted into the FDA’s Emerging Technology Program due to the innovation and potential impact of its drug delivery approach.

Therapeutic areas: ImmunologyEndocrinology
Modalities: NanoparticlePolymer-drug conjugate therapyBiologic (focus on oral delivery of biologics)
Industry: Biotech

Drug pipeline

1 asset

Toralgen oral insulin

Preclinical

Partnerships

Collaborations with Yale University scientists for foundational research and ongoing developmentEngaged with pharmaceutical partners for upcoming trials (specific names not disclosed)

Beyond the preview

Go deeper on Toralgen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toralgen.

Explore the full profile